PDF herunterladen
CC BY-NC-ND 4.0 · South Asian J Cancer 2022; 11(01): 062-067
DOI: 10.1055/s-0041-1731599
Original Article
Leukemia – Lymphoma and Myeloma

Hematopoietic Stem Cell Transplant for Hematological Malignancies: Experience from a Tertiary Care Center in Northern India and Review of Indian Data

Sanjeev Kumar Sharma
1   Center for Bone Marrow Transplant, BLK Super Speciality Hospital, New Delhi, India
,
Dharma Choudhary
1   Center for Bone Marrow Transplant, BLK Super Speciality Hospital, New Delhi, India
,
Divya Doval
1   Center for Bone Marrow Transplant, BLK Super Speciality Hospital, New Delhi, India
,
Vipin Khandelwal
1   Center for Bone Marrow Transplant, BLK Super Speciality Hospital, New Delhi, India
,
Rasika Setia 
1   Center for Bone Marrow Transplant, BLK Super Speciality Hospital, New Delhi, India
,
Tina Dadu
1   Center for Bone Marrow Transplant, BLK Super Speciality Hospital, New Delhi, India
,
Anil Handoo
1   Center for Bone Marrow Transplant, BLK Super Speciality Hospital, New Delhi, India
› Institutsangaben Funding None.
› Weitere Informationen
   Lizenzen und Reprints

Abstract

Zoom Image
Sanjeev Kumar Sharma

Hematopoietic stem cell transplantation (HSCT) is the preferred treatment for high-risk and relapsed/refractory hematological malignancies. Moreover, with the improved supportive care and increasing acceptance of haploidentical transplantations as an alternative treatment modality, more patients are opting for HSCT as a definite treatment for hematological malignancies. We report here the real-world data and outcome of HSCT done for hematological malignancies at our transplant center. Five hundred and sixteen patients underwent HSCT from August 2010 to November 2019. The most common indications for allogeneic and autologous HSCT were acute myeloid leukemia and multiple myeloma, respectively. The 5-year overall survival and disease-free survival for all transplants were 65% and 33%, respectively. Though outcome of matched sibling donor allogeneic transplant is better than haploidentical donor (HID) transplant, patients having only HID can still be considered for allogeneic HSCT for high-risk diseases. The most common cause of death was infections followed by relapse of the disease.

Keywords

leukemia - lymphoma - myeloma - matched sibling donor - allogeneic - haploidentical - stem cell transplant - overall survival - infections - GVHD

Financial Disclosure

The authors declare that this study received no financial support.


Ethics Committee Approval

The protocol and informed consent was approved by the Hospital ethical committee. Informed consent was taken from all the patients.




Publikationsverlauf

Artikel online veröffentlicht:
15. Oktober 2021

© 2021. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Bacigalupo A, Ballen K, Rizzo D. et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15 (12) 1628-1633
    CrossrefPubMedGoogle Scholar
  • 2 Sharma SK, Choudhary D, Gupta N. et al. Cost of hematopoietic stem cell transplantation in India. Mediterr J Hematol Infect Dis 2014; 6 (01) e2014046
    CrossrefPubMedGoogle Scholar
  • 3 Malhotra P, Yanamandra U, Khadwal A. et al. Autologous stem cell transplantation for multiple myeloma: single centre experience from North India. Indian J Hematol Blood Transfus 2018; 34 (02) 261-267
    CrossrefPubMedGoogle Scholar
  • 4 Kumar L, Ramavath D, Kataria B. et al. for AIIMS Myeloma Group. High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: predictors of long-term outcome. Indian J Med Res 2019; 149 (06) 730-739
    CrossrefPubMedGoogle Scholar
  • 5 Kulkarni U, Devasia AJ, Korula A. et al. Clinical outcomes in multiple myeloma post-autologous transplantation-a single centre experience. Indian J Hematol Blood Transfus 2019; 35 (02) 215-222
    CrossrefPubMedGoogle Scholar
  • 6 Nair R, Arora N, Mallath MK. Epidemiology of non-Hodgkin's lymphoma in India. Oncology 2016; 91 (Suppl. 01) 18-25
    CrossrefPubMedGoogle Scholar
  • 7 Perry AR, Goldstone AH. High-dose therapy for diffuse large-cell lymphoma in first remission. Ann Oncol 1998; 9 (Suppl. 01) S9-S14
    CrossrefPubMedGoogle Scholar
  • 8 Philip T, Guglielmi C, Hagenbeek A. et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333 (23) 1540-1545
    CrossrefPubMedGoogle Scholar
  • 9 Prakash G, Sharma A, Raina V, Kumar L, Sharma MC, Mohanti BK. B cell non-Hodgkin's lymphoma: experience from a tertiary care cancer center. Ann Hematol 2012; 91 (10) 1603-1611
    CrossrefPubMedGoogle Scholar
  • 10 Gisselbrecht C, Van Den Neste E. How I manage patients with relapsed/refractory diffuse large B cell lymphoma. Br J Haematol 2018; 182 (05) 633-643
    CrossrefPubMedGoogle Scholar
  • 11 Kumar L, Ganessan P, Ghosh I, Panda D, Gogia A, Mandhania S. Autologous blood stem cell transplantation for Hodgkin and non-Hodgkin lymphoma: complications and outcome. Natl Med J India 2010; 23 (06) 330-335
    PubMedGoogle Scholar
  • 12 Chen Y-B, Lane AA, Logan B. et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2015; 21 (06) 1046-1053
    CrossrefPubMedGoogle Scholar
  • 13 Raut LS, Chakrabarti PP. Management of relapsed-refractory diffuse large B cell lymphoma. South Asian J Cancer 2014; 3 (01) 66-70
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 14 Ganapule A, Nemani S, Korula A. et al. Allogeneic stem cell transplant for acute myeloid leukemia: evolution of an effective strategy in India. J Glob Oncol 2017; 3 (06) 773-781
    CrossrefPubMedGoogle Scholar
  • 15 Sharma SK, Choudhary D, Doval D. et al. Myeloablative versus reduced intensity conditioning regimens for allogeneic hematopoietic stem cell transplant for acute myeloid leukemia and myelodysplastic syndrome: a retrospective analysis. Indian J Hematol Blood Transfus 2020; ••• DOI: 10.1007/s12288-020-01386-6.
    CrossrefPubMedGoogle Scholar
  • 16 Arora S, Pushpam D, Tiwari A. et al. Allogeneic hematopoietic stem cell transplant in pediatric acute myeloid leukemia: lessons learnt from a tertiary care center in India. Pediatr Transplant 2021; 25 (03) e13918
    CrossrefPubMedGoogle Scholar
  • 17 Kanakry CG, de Lima MJ, Luznik L. Alternative donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Semin Hematol 2015; 52 (03) 232-242
    CrossrefPubMedGoogle Scholar
  • 18 Wang Y, Liu Q-F, Xu L-P. et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood 2015; 125 (25) 3956-3962
    CrossrefPubMedGoogle Scholar
  • 19 Ringdén O, Labopin M, Ciceri F. et al. Is there a stronger graft-versus-leukemia effect using HLA-haploidentical donors compared with HLA-identical siblings?. Leukemia 2016; 30 (02) 447-455
    CrossrefPubMedGoogle Scholar
  • 20 Nataraj KS, Prabhu S, Bhat S. et al. Hematopoietic stem cell transplant outcomes in patients with acute myeloid leukemia from a tertiary care center in South India. Biol Blood Marrow Transplant 2020; 26 (03) S123-S124
    CrossrefGoogle Scholar
  • 21 Jaiswal SR, Chakrabarti A, Chatterjee S. et al. Haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide in children with advanced acute leukemia with fludarabine-, busulfan-, and melphalan-based conditioning. Biol Blood Marrow Transplant 2016; 22 (03) 499-504
    CrossrefPubMedGoogle Scholar
  • 22 Fabricius WA, Ramanathan M. Review on haploidentical hematopoietic cell transplantation in patients with hematologic malignancies. Adv Hematol 2016; 2016: 5726132
    CrossrefPubMedGoogle Scholar
  • 23 Sharma SK. What a clinical hematologist should know about T cells?. Int Blood Res Rev 2020; 20-32
    CrossrefGoogle Scholar
  • 24 Gokarn A, Bonda A, Mathew L. et al. High dose chemotherapy with autologous stem cell transplantation for multiple myeloma: outcomes at Tata Memorial Centre. Clin Lymphoma Myeloma Leuk 2017; 17 (01) e126
    CrossrefGoogle Scholar
  • 25 Sharma SK, Choudhary D, Kumar M. et al. Stem cell transplant for multiple myeloma: a single center experience from Northern India. J Hematol Oncol 2018; 31: 1010
    Google Scholar
  • 26 Aggarwal M, Agrawal N, Yadav N. et al. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma. Ann Hematol 2018; 97 (10) 1869-1877
    CrossrefPubMedGoogle Scholar
  • 27 Naithani R, Dayal N, Rai R, Pathak S, Singh M. Autologous hematopoietic stem cell transplantation for multiple myeloma in India. Indian J Hematol Blood Transfus 2018; 34 (03) 564-565
    CrossrefPubMedGoogle Scholar
  • 28 Yanamandra U, Malhotra P. Stem cell transplantation in multiple myeloma: very much alive and kicking. Indian J Hematol Blood Transfus 2019; 35 (02) 205-207
    CrossrefPubMedGoogle Scholar
  • 29 Kumar J, Nair R, Radhakrishnan V. et al. Autologous Stem cell transplantation in multiple myeloma: experience of a single center from Eastern India. Clin Lymphoma Myeloma Leuk 2019; 19: S326
    CrossrefGoogle Scholar
  • 30 Raut S, Shah S, Shah K. et al. Improving outcome of Hodgkin's disease with autologous hematopoietic stem cell transplantation. Indian J Hematol Blood Transfus 2016; 32 (02) 176-181
    CrossrefPubMedGoogle Scholar
  • 31 Shah CA, Karanwal A, Desai M, Pandya M, Shah R, Shah R. Hematopoietic stem-cell transplantation in the developing world: experience from a center in Western India. J Oncol 2015; 2015: 710543
    PubMedGoogle Scholar
  • 32 Khattry N, Laskar S, Sengar M. et al. Long term clinical outcomes of adult hematolymphoid malignancies treated at Tata Memorial Hospital: an institutional audit. Indian J Cancer 2018; 55 (01) 9-15
    CrossrefPubMedGoogle Scholar